Mar 4 |
Bayer pays $310M to buy into BridgeBio heart drug
|
Mar 4 |
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe
|
Mar 4 |
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
|
Mar 4 |
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
|
Feb 24 |
BridgeBio Pharma Full Year 2023 Earnings: Misses Expectations
|
Feb 22 |
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
|
Feb 22 |
BridgeBio Pharma Inc (BBIO) Reports Q4 and Full Year 2023 Financials, Advances Key Clinical Trials
|
Feb 22 |
BridgeBio Pharma GAAP EPS of -$0.96 misses by $0.04, revenue of $1.75M misses by $2.04M
|
Feb 22 |
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
|
Feb 15 |
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
|